Wegovy pill vs Rybelsus: what’s the difference?
“Wegovy pill” is a term that’s gathering a lot of interest on social media platforms. It refers to a new FDA-approved oral semaglutide tablet doctors can prescribe for weight management. This gets attention because most people are aware of the tremendous changes that the introduction of GLP-1 medications such as Ozempic and Wegovy have made in […]
Diabetes management is the next frontier
Type 2 diabetes (T2D) is one of the most prevalent chronic conditions in the general U.S. population, ranking alongside hypertension (high blood pressure), high cholesterol, and arthritis as one of the four most common chronic diseases. At this point in time, diabetes cannot be completely cured. The four main components of the current approach that […]
A Smarter Way to Understand Prediabetes
Both prediabetes and diabetes are very common conditions. Studies have shown that about 38 million adults in the US have been diagnosed as diabetics, which is nearly 15% of the US adult population. Prediabetes is far more common. Reliable estimates put the numbers at just below 100 million adults in the US, although the majority […]
Exercise Is Important for Teens With Type 2 Diabetes
Depression in diabetic teenagers is a real pressure point for many families and clinics. Teens who live with type 2 diabetes carry the daily load of blood sugar checks, food decisions, and health worries. When low mood, sadness, or loss of interest are added on top, life can feel very heavy. New work in physical […]
What to do if GLP-1 Medications Reduce Libido
It’s a difficult question to even ask. Can weight-loss wonder drugs like Ozempic and Wegovy also reduce libido? There’s been a wave of fascination, almost a collective obsession, with this new class of GLP-1 drugs, often described as revolutionary. One topic, however, isn’t being discussed nearly enough. It sits quietly beneath the surface, weighed down […]
Is Rybelsus the same as semaglutide?
There has been a tidal wave of interest in the new “wonder drugs” that are based on chemicals called glucagon-like peptide-1 receptor agonists (GLP-1RA), which have revolutionized treatments of a wide range of potentially serious diseases. Many people are now familiar with the common terms associated with these new treatments, such as Ozempic, Mounjaro, semaglutide […]
Exploring treatment options for fatty liver disease in adults over 40
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is becoming one of the most common causes of chronic liver illness among adults over 40. It is strongly linked to obesity, type 2 diabetes, high blood pressure, and high cholesterol. When ignored, MASLD can progress to liver scarring, cirrhosis, and […]
GLP-1 Medications and Aging: Benefits and Risks for Older Adults
GLP-1 medications like Ozempic and Mounjaro are gaining popularity among older adults not only for managing diabetes but also for their potential anti-aging effects. But alongside the benefits, there are real risks, especially for those over 65. Understanding both sides is key to making informed decisions that support healthy aging. GLP-1 drugs revolutionized the world […]
Common GLP-1 Side Effects Made Simple
Drugs like Ozempic, Wegovy, Zepbound, and Mounjaro have changed the way doctors manage type 2 diabetes and obesity. These medications, called GLP-1 receptor agonists, help the body produce more insulin after meals, slow down digestion, and reduce appetite. The results can be dramatic, including weight loss, improved blood sugar control, and a reduced risk of heart disease. But there’s […]
Ozempic, Chronic Kidney Disease, and Diabetes
In January 2025, the FDA approved Ozempic (semaglutide) to help treat patients with chronic kidney disease and diabetes. Semaglutide belongs to a group of drugs called glucagon-like peptide-1 receptor agonists (GLP1-RAs), which were originally approved to help control blood sugar in people with type 2 diabetes. Other forms of GLP1-RAs include Mounjaro, Wegovy, semaglutide, and […]
